CONTINEUM THERAPEUTICS REPORTS THIRD-QUARTER 2026 FINANCIAL RESULTS
Contineum Therapeutics, Inc. (CTNM) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 CONTINEUM THERAPEUTICS REPORTS THIRD-QUARTER 2026 FINANCIAL RESULTS SAN DIEGO – November 3, 2026 – Contineum Therapeutics, Inc. (NASDAQ: CTNM) (Contineum or the Company), a clinical-stage biopharmaceutical company pioneering differentiated small molecule therapies fo
How this was made
The 30-second read
Why it matters
The disclosed net loss widening and cash position may prompt short‑term sell pressure, but the stated runway supports longer‑term confidence.
Market read
Micro‑cap biotech earnings release; relevant for traders tracking small‑cap biotech sentiment and cash‑runway assessments.
What to watch
Progress of PIPE‑791 trial and potential partnership announcements could offset short‑term weakness.
Contineum Therapeutics reports third-quarter 2026 financial results, with $244.5 million in cash, cash equivalents and marketable securities and cash runway through mid-2029.
The Company reported rising clinical-development spending and a wider net loss while maintaining stated cash resources sufficient to fund planned operations through mid-2029 and advancing enrollment infrastructure for PROPEL-IPF.
Key metrics
shortened, hover for the filing’s print| Metric | Value | q/q | y/y |
|---|---|---|---|
| Research and development expenses, three months ended September 30, 2026GAAP | $15.98M | – | 45 percent increase |
| General and administrative expenses, three months ended September 30, 2026GAAP | $4.98M | – | 26 percent increase |
| Total operating expenses, three months ended September 30, 2026GAAP | $20.97M | – | – |
| Loss from operations, three months ended September 30, 2026GAAP | −$20.97M | – | – |
| Interest income, three months ended September 30, 2026GAAP | $2.36M | – | – |
| Other income (expense), net, three months ended September 30, 2026GAAP | −$93K | – | – |
| Total other income, net, three months ended September 30, 2026GAAP | $2.27M | – | – |
| Net loss, three months ended September 30, 2026GAAP | −$18.70M | – | – |
| Unrealized gain (loss) on marketable securities, three months ended September 30, 2026GAAP | −$934K | – | – |
| Comprehensive loss, three months ended September 30, 2026GAAP | −$19.63M | – | – |
| Net loss per share, basic and diluted, three months ended September 30, 2026GAAP | $(0.49) | – | – |
| Weighted-average shares of common stock outstanding, basic and diluted, three months ended September 30, 2026GAAP | 38,390,234 | – | – |
| Research and development expenses, nine months ended September 30, 2026GAAP | $40.33M | – | – |
| General and administrative expenses, nine months ended September 30, 2026GAAP | $14.96M | – | – |
| Total operating expenses, nine months ended September 30, 2026GAAP | $55.30M | – | – |
| Loss from operations, nine months ended September 30, 2026GAAP | −$55.30M | – | – |
| Interest income, nine months ended September 30, 2026GAAP | $7.21M | – | – |
| Other income (expense), net, nine months ended September 30, 2026GAAP | −$216K | – | – |
| Total other income, net, nine months ended September 30, 2026GAAP | $6.99M | – | – |
| Net loss, nine months ended September 30, 2026GAAP | −$48.31M | – | – |
| Unrealized gain (loss) on marketable securities, nine months ended September 30, 2026GAAP | −$1.77M | – | – |
| Comprehensive loss, nine months ended September 30, 2026GAAP | −$50.07M | – | – |
| Net loss per share, basic and diluted, nine months ended September 30, 2026GAAP | $(1.28) | – | – |
| Weighted-average shares of common stock outstanding, basic and diluted, nine months ended September 30, 2026GAAP | 37,736,217 | – | – |
| Cash and cash equivalents, September 30, 2026GAAP | $75.20M | – | – |
| Marketable securities, September 30, 2026GAAP | $169.3M | – | – |
| Total current assets, September 30, 2026GAAP | $249.7M | – | – |
| Total assets, September 30, 2026GAAP | $257.0M | – | – |
| Total current liabilities, September 30, 2026GAAP | $8.03M | – | – |
| Total liabilities, September 30, 2026GAAP | $11.57M | – | – |
| Total stockholders' equity, September 30, 2026GAAP | $245.4M | – | – |
Amounts quoted below without a unit are in thousands, as in the filing’s tables. Per-share figures are as printed.
through mid-2029 outlook
- NoteContineum believes its cash resources are sufficient to fund its planned operations through mid-2029.
What drove it
- Research and development expense increased primarily due to higher expenses related to the PIPE-791 IPF program and employee-related costs.
- General and administrative expense increased primarily due to higher stock-based compensation and employee-related costs.
- Over 100 sites were online in 16 countries for PROPEL-IPF enrollment.
Concerns
- The Company reported a net loss of $18.7 million for the three months ended September 30, 2026, compared with $12.8 million for the third quarter of 2025.
- The Company is heavily dependent on the success of PIPE-791 and PIPE-307, both of which are in the early stages of clinical development.
- The Company may use its capital resources sooner than expected and they may be insufficient to allow the Company to achieve its anticipated milestones.
What to watch
- The pace of enrollment in PROPEL-IPF, the global Phase 2 trial of PIPE-791 in idiopathic pulmonary fibrosis.
- The change from baseline through week 26 in absolute forced vital capacity (FVC mL), the trial's primary efficacy endpoint.
- The Company's stated cash runway through mid-2029 and clinical-development spending for PIPE-791.
Balance sheet and cash flow
- Cash, cash equivalents and marketable securities were $244.5 million as of September 30, 2026.
- Cash and cash equivalents were $75,198 (in thousands) as of September 30, 2026.
- Marketable securities were $169,286 (in thousands) as of September 30, 2026.
- Total assets were $256,988 (in thousands) and total liabilities were $11,570 (in thousands) as of September 30, 2026.
Analysis
Contineum remains a clinical-stage company and reported no revenue in the filing. Third-quarter research and development expense was $16.0 million, a 45 percent increase from the third quarter of 2025, primarily reflecting the PIPE-791 IPF program and employee-related costs. General and administrative expense was $5.0 million, a 26 percent increase, primarily due to stock-based compensation and employee-related costs.
The higher expense base resulted in a net loss of $18.7 million for the three months ended September 30, 2026, compared with $12.8 million for the third quarter of 2025. Loss from operations was $(20,966) (in thousands), compared with $(14,932) (in thousands). Interest income was $2,362 (in thousands), compared with $1,957 (in thousands), providing partial offset to operating expenses.
Liquidity was the principal financial support disclosed in the release. Cash, cash equivalents and marketable securities were $244.5 million as of September 30, 2026. The Company stated that these resources are sufficient to fund planned operations through mid-2029. The filing reported total liabilities of $11,570 (in thousands) and total stockholders' equity of $245,418 (in thousands) at September 30, 2026.
Operationally, the Company said PROPEL-IPF had more than 100 sites online in 16 countries. The global Phase 2 trial evaluates once-daily oral PIPE-791 with 26 weeks of treatment in approximately 324 IPF patients, with change from baseline through week 26 in absolute forced vital capacity as the primary efficacy endpoint. The key reported developments to monitor are enrollment execution, clinical-trial progress and the trajectory of PIPE-791 development expense against the stated runway through mid-2029.
Management, verbatim
We continue to expand our footprint for PROPEL-IPF, with over 100 sites now online in 16 countries to facilitate a steady pace of enrollment. With a projected cash runway that extends through mid-2029, we are well positioned with capital resources one year past the estimated completion of our idiopathic pulmonary fibrosis (IPF) trial.
Carmine Stengone, CEO, Contineum Therapeutics
We believe the LPAR1 class can be the ideal backbone for combination treatments. Our LPAR1 antagonist, PIPE-791, is potentially differentiated in key ways including a favorable safety and tolerability profile, sustained target engagement which we believe has the potential for improved efficacy, and superior convenience in a one-time daily, low oral dose with no titration required for patients.
Carmine Stengone, CEO, Contineum Therapeutics
Not in the filing
stated, not guessed- Revenue and revenue comparisons were not reported.
- Revenue segments were not reported.
- Gross profit and gross margin were not reported.
- Non-GAAP operating income, net income, EPS, or other non-GAAP measures were not reported.
- Operating cash flow and free cash flow were not reported.
- Debt was not reported.
- Share repurchases and dividends were not reported.
- Formal revenue, gross margin, operating expense, or tax-rate guidance was not reported.
- Prior-quarter comparisons were not reported.
- Prior-year balance-sheet comparisons were not reported; the balance sheet instead includes December 31, 2025 comparative amounts.
Written by an AI language model from the company’s SEC earnings filing (Form 8-K Item 2.02, or Form 6-K for a foreign private issuer). Every figure was checked against the filing text, and a metric whose value, prior period and change do not add up is dropped from the metrics. The model can still misread a table, in the metrics or in the text, so check a number in the filing before you rely on it. Consensus estimates, price targets and share-price reactions are not shown because they are not in the filing. AI-generated research, not investment advice.
Background
SEC Form 8‑K filing provides the first public disclosure of Contineum Therapeutics' third‑quarter 2026 financials.
Ticker impact
Contineum Therapeutics filed an 8‑K reporting Q3 2026 results: cash $244.5 M, R&D $16.0 M, net loss $18.7 M.
likely modest downside pressure as investors digest higher loss and cash balance
First‑report of the quarter's financials for a micro‑cap biotech; loss increase and cash level are material to short‑term sentiment.
Market effects
Biotech sector may see slight pressure as a peer reports higher loss, but cash runway remains adequate.
US small‑cap biotech investors may adjust positions; limited broader market effect.
Minimal global impact beyond niche biotech investors.
Counterpoint
Cash runway to 2029 could support a bounce if investors focus on long‑term pipeline rather than short‑term loss.
Key entities
- companyContineum Therapeutics, Inc.
Clinical‑stage biopharma developing LPA1 antagonist PIPE‑791.
